Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111,

Slides:

Advertisements

Similar presentations

THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.

Advertisements

Advanced Cancer Topics Journal Review 4/16/2009 AD.

General classes of vaccines An induced mobilization of the immune response for the purpose of therapeutic benefit. Preventative: infectious agents Therapeutic:

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Ablation of Fbxw7 Eliminates Leukemia-Initiating Cells by Preventing Quiescence Shoichiro Takeishi, Akinobu Matsumoto, Ichiro Onoyama, Kazuhito Naka, Atsushi.

Schema for a human microbiome study

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

by Jennifer Couzin-Frankel

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

Inhibitor of MAP kinase activation blocks colon cancer growth

Advances in Specific Immunotherapy for Prostate Cancer

Types of Tumor Vascularization

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer

The PI3K/Akt signalling and its activation in cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The hallmarks of adenovirus infection

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Figure 1 Targets for monoclonal antibodies in B-cell lineages

Schematic diagram of antibody drug conjugate

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 6 Combination therapy for HCC

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Minyoung Her, MD, Arthur Kavanaugh, MD

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

(A) An overview of the JAK/STAT signalling pathway.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Molecular approaches to HER2 targeted therapy

An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.

ADVANCED TARGETING SYSTEMS for specific elimination of cell types

Model of the function of TBX2 in RMS.

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer Figure 2 from Mitchell and Neal British.

Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and.

Figure 2 Site of action of checkpoint inhibitors and agonists being

Volume 23, Issue 3, Pages (March 2013)

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Figure 1 from M Holderfield

Molecular features of the colon during homeostasis and carcinogenesis

Figure 1 from T Schenk et al.

HDACs class I, II, IV mutations in human cancer

Translating Germline Cancer Risk into Precision Prevention

In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.

Figure 1 Mechanisms of action of immunotherapy modalities

Mitochondrial priming model

aSIRTing Control over Cancer Stem Cells

Spectrum of cellular processes regulated by AXL activity

Figure 1 from D’Incalci et al.

Involvement of actin cytoskeletal reorganisation in EMT

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

John P. Sundberg, Lloyd E. King

Target antigens for ADCs in solid tumours

Macrophage differentiation and their role in tumourigenesis

Model of EphA/ephrin-A expression in GBM.

by Jennifer Couzin-Frankel

A schematic representation of NOTCH signaling through DAB1–ABL–TRIO–RHO that stimulates colorectal cancer invasion and metastasis. A schematic representation.

Presentation transcript:

Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111, 1054-1059; doi:10.1038/bjc.2014.259 Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2014 Cancer Research UK.